CAR T-cell treatment of high-risk multiple myeloma: will there be a cure?
- PMID: 36891744
- PMCID: PMC10542833
- DOI: 10.3324/haematol.2023.282896
CAR T-cell treatment of high-risk multiple myeloma: will there be a cure?
Comment on
-
Impact of high-risk disease on the efficacy of chimeric antigen receptor T-cell therapy for multiple myeloma: a meta-analysis of 723 patients.Haematologica. 2023 Oct 1;108(10):2799-2802. doi: 10.3324/haematol.2022.282510. Haematologica. 2023. PMID: 36815380 Free PMC article. No abstract available.
References
-
- Barlogie B, Hall R, Zander A, Dicke K, Alexanian R. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood. 1986;67(5):1298-1301. - PubMed
-
- Gahrton G, Ringden O, Lonnqvist B, Lindquist R, Ljungman P. Bone marrow transplantation in three patients with multiple myeloma. Acta Med Scand. 1986;219(5):523-527. - PubMed
-
- Gahrton G, lacobelli S, Bjorkstrand B, et al. . Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood. 2013;121(25):5055-5063. - PubMed
-
- Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. G raft-versus-myeloma effect: proof of principle. Blood. 1996;87(3):1196-1198. - PubMed
-
- Aschan J, Lonnqvist B, Ringden O, Kumlien G, Gahrton G. Graft-versus-myeloma effect. Lancet. 1996;348(9023):346. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
